マーケットレポート詳細
血液検査の世界市場：製品サービス別、技術別2028年予測
Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年10月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文 253ページになります。
- 商品コード：MAM3413
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
血液検査の世界市場規模は2023年で24億ドル、2028年に34億ドル、市場の平均年成長率は7.2%増加すると見込んでいます。
レポートは血液検査の世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製品サービス別市場、技術別市場、等）を中心に構成されています。また競合状況、主要企業情報（11社）、規制状況、ケーススタディなどの分析も加味し、血液検査市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆血液検査の世界市場予測2021-2028年
・市場規模(US$)
◆製品サービス別、市場-2028年
試薬キット
・NAT試薬、キット
・ELISA試薬、キット
・その他試薬、キット
器具
・レンタル購入
・一括購入
ソフトウェア、サービス
※(市場規模US$)
◆技術別、市場-2028年
核酸増幅検査（NAT）
・転写媒介増幅（TMA）
・リアルタイムポリメラーゼ連鎖反応（RT-PCR）
血清、免疫学的検定
・化学発光免疫測定法（CLIA）
・蛍光免疫測定法（FIA）
・酵素免疫測定法（CI、ELISA）
迅速検査
ウェスタンブロッティング
次世代シーケンシング（NGS）
※(市場規模US$)
◆エンドユーザー別、市場-2028年
・血液バンク
・病院
※(市場規模US$)
◆主要国地域別市場-2028年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国
・インド、オーストラリア
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
※地域、国別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス
・平均価格分析
・特許分析
・サプライチェーン分析
・エコシステム分析
・ファイブフォース分析
・規制状況
・ケーススタディ分析
・競合状況
・市場シェア分析
◆血液検査の主要企業プロフィール動向
・F HOFFMANN-LA ROCHE LTD
・GRIFOLS, SA
・ABBOTT LABORATORIES
・BIO-RAD LABORATORIES, INC
・DIASORIN
・BIOMÉRIEUX
・BD
・DANAHER (BECKMAN COULTER, INC)
・HOLOGIC, INC
・SIEMENS HEALTHINEERS AG
・THERMO FISHER SCIENTIFIC, INC
その他企業
・ORTHO CLINICAL DIAGNOSTICS
・MERCK KGAA
・REVVITY (PART OF PERKINELMER INC)
・BIO-TECHNE
・GFE
・TRINITY BIOTECH
・J MITRA & CO PVT LTD
・MINDRsAY
・MACCURA BIOTECHNOLOGY CO, LTD
・IMMUCOR, INC
・CELLABS
・ABNOVA CORPORATION
・ENZO BIOCHEM, INC
・TULIP DIAGNOSTICS PVT LTD
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 34
1.3 MARKET SCOPE 35
1.3.1 BLOOD SCREENING MARKET 35
1.3.2 REGIONS COVERED 36
1.4 YEARS CONSIDERED 36
1.5 CURRENCY CONSIDERED 37
1.6 LIMITATIONS 37
1.7 STAKEHOLDERS 371.8 SUMMARY OF CHANGES 37
1.9 RECESSION IMPACT 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.2 RESEARCH APPROACH 39
・ FIGURE 1 BLOOD SCREENING MARKET: RESEARCH DESIGN METHODOLOGY 39
2.2.1 SECONDARY DATA 40
2.2.1.1 KEY DATA FROM SECONDARY SOURCES 40
2.2.2 PRIMARY DATA 41
2.2.2.1 PRIMARY SOURCES 42
2.2.2.2 KEY DATA FROM PRIMARY SOURCES 42
2.2.2.3 KEY INDUSTRY INSIGHTS 43
2.2.2.4 BREAKDOWN OF PRIMARY INTERVIEWS 44
・ FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 44
2.3 MARKET SIZE ESTIMATION 45
2.3.1 BOTTOM-UP APPROACH 45
2.3.1.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH 45
・ FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 45
2.3.1.2 APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS 46
2.3.1.3 GROWTH FORECAST 46
2.3.1.4 CAGR PROJECTIONS 46
・ FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
2.3.2 TOP-DOWN APPROACH 47
・ FIGURE 6 BLOOD SCREENING MARKET: TOP-DOWN APPROACH 47
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 48
・ FIGURE 7 DATA TRIANGULATION METHODOLOGY 48
2.5 MARKET SHARE ANALYSIS 49
2.6 STUDY ASSUMPTIONS 49
2.7 GROWTH RATE ASSUMPTIONS 50
2.8 RISK ASSESSMENT 50
2.8.1 RISK ASSESSMENT ANALYSIS 50
2.9 RECESSION IMPACT ANALYSIS 50
3 EXECUTIVE SUMMARY 52
・ FIGURE 8 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 52
・ FIGURE 9 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 53
・ FIGURE 10 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
・ FIGURE 11 BLOOD SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 54
4 PREMIUM INSIGHTS 55
4.1 BLOOD SCREENING MARKET OVERVIEW 55
・ FIGURE 12 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 55
4.2 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 56
・ FIGURE 13 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.3 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 56
・ FIGURE 14 NUCLEIC ACID TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.4 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 57
・ FIGURE 15 BLOOD BANKS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57
4.5 BLOOD SCREENING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 57
・ FIGURE 16 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE FROM 2023 TO 2028 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
・ FIGURE 17 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.2.1 DRIVERS 59
5.2.1.1 INCREASING BLOOD DONATIONS 59
5.2.1.2 RISING PREVALENCE OF INFECTIOUS DISEASES 60
5.2.2 RESTRAINTS 60
5.2.2.1 HIGH COST OF BLOOD SCREENING TECHNOLOGIES 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 RISING TECHNOLOGICAL ADVANCEMENTS 61
5.2.3.2 HIGH GROWTH POTENTIAL OF EMERGING ECONOMIES 61
5.2.4 CHALLENGES 62
5.2.4.1 USAGE OF LOW-SENSITIVITY SCREENING TESTS 62
5.2.4.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 62
5.3 PRICING ANALYSIS 63
5.3.1 PRICING MODEL ANALYSIS 63
・ TABLE 1 INDICATIVE PRICING ANALYSIS FOR BLOOD SCREENING PRODUCTS 63
5.3.2 AVERAGE SELLING PRICE TREND 63
・ TABLE 2 AVERAGE SELLING PRICE ANALYSIS OF BLOOD SCREENING PRODUCTS 63
5.3.3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS, BY KEY PLAYER 64
・ TABLE 3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS 64
5.4 PATENT ANALYSIS 65
5.4.1 PATENT ANALYSIS OF NUCLEIC ACID AMPLIFICATION TECHNOLOGIES 65
5.4.2 BLOOD SCREENING MARKET: LIST OF MAJOR PATENTS 66
5.5 VALUE CHAIN ANALYSIS 66
・ FIGURE 18 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 67
5.6 SUPPLY CHAIN ANALYSIS 67
・ FIGURE 19 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM ANALYSIS 68
・ FIGURE 20 BLOOD SCREENING MARKET: ECOSYSTEM MAP 69
5.7.1 BLOOD SCREENING MARKET: ECOSYSTEM ROLE 69
5.8 PORTER’S FIVE FORCES ANALYSIS 70
・ TABLE 4 BLOOD SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 70
5.8.1 THREAT OF NEW ENTRANTS 70
5.8.2 THREAT OF SUBSTITUTES 70
5.8.3 BARGAINING POWER OF BUYERS 70
5.8.4 BARGAINING POWER OF SUPPLIERS 70
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.9 REGULATORY LANDSCAPE 71
・ TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
・ TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
・ TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
・ TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.9.1 NORTH AMERICA 72
5.9.1.1 US 72
5.9.1.2 CANADA 72
5.9.2 EUROPE 73
・ TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 73
5.9.3 ASIA PACIFIC 74
5.9.3.1 CHINA 74
5.9.3.2 JAPAN 74
・ TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 74
5.9.3.3 INDIA 74
5.9.4 LATIN AMERICA 74
5.9.4.1 BRAZIL 75
5.9.5 MIDDLE EAST 75
5.10 TRADE ANALYSIS 75
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 75
・ TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 75
・ TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 76
5.11 TECHNOLOGY ANALYSIS 76
5.12 KEY CONFERENCES AND EVENTS 77
・ TABLE 13 BLOOD SCREENING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023 −2024) 77
5.13 PESTLE ANALYSIS 78
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.14.1 REVENUE SHIFT IN BLOOD SCREENING MARKET 79
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
・ FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS 79
・ TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS (%) 80
5.15.2 BUYING CRITERIA 80
・ FIGURE 22 KEY BUYING CRITERIA FOR BLOOD SCREENING PRODUCTS 80
・ TABLE 15 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 80
5.16 CASE STUDY ANALYSIS 81
5.16.1 CASE STUDY 1: OPTIMIZATION OF HBSAG QUANTITATIVE ELISA 81
5.16.2 CASE STUDY 2: CLINICAL EFFICACY OF NAT WITH ELISA 81
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE 82
6.1 INTRODUCTION 83
・ TABLE 16 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83
6.2 REAGENTS & KITS 83
・ TABLE 17 KEY PRODUCTS FOR REAGENTS & KITS 84
・ TABLE 18 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 84
・ TABLE 19 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 85
6.2.1 NAT REAGENTS & KITS 85
6.2.1.1 HIGH SENSITIVITY TO DRIVE MARKET 85
・ TABLE 20 KEY PRODUCTS FOR NAT REAGENTS & KITS 86
・ TABLE 21 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 87
・ TABLE 22 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 87
6.2.2 ELISA REAGENTS & KITS 87
6.2.2.1 EASE OF USE AND COST-EFFECTIVENESS TO DRIVE MARKET 87
・ TABLE 23 KEY PRODUCTS FOR ELISA REAGENTS & KITS 89
・ TABLE 24 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 89
・ TABLE 25 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 90
6.2.3 OTHER REAGENTS & KITS 90
・ TABLE 26 KEY PRODUCTS FOR OTHER REAGENTS & KITS 90
・ TABLE 27 BLOOD SCREENING MARKET FOR OTHER REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 91
6.3 INSTRUMENTS 91
・ TABLE 28 KEY PRODUCTS FOR INSTRUMENTS 92
・ TABLE 29 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 92
・ TABLE 30 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 93
6.3.1 RENTAL PURCHASE 93
6.3.1.1 REDUCED LIABILITY WITH LIMITED FINANCIAL LOSSES TO PROPEL MARKET 93
・ TABLE 31 BLOOD SCREENING MARKET FOR RENTAL PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 93
6.3.2 OUTRIGHT PURCHASE 94
6.3.2.1 AVAILABILITY OF GOVERNMENT SUPPORT TO DRIVE MARKET 94
・ TABLE 32 BLOOD SCREENING MARKET FOR OUTRIGHT PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 94
6.4 SOFTWARE & SERVICES 94
6.4.1 RISING DEMAND ACROSS EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 94
・ TABLE 33 KEY PRODUCTS FOR SOFTWARE & SERVICES 95
・ TABLE 34 BLOOD SCREENING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 95
7 BLOOD SCREENING MARKET, BY TECHNOLOGY 96
7.1 INTRODUCTION 97
・ TABLE 35 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 97
7.2 NUCLEIC ACID TESTS (NAT) 97
・ TABLE 36 KEY PRODUCTS IN NAT MARKET 98
・ TABLE 37 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY REGION, 2021–2028 (USD MILLION) 99
・ TABLE 38 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 99
7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 99
7.2.1.1 HIGH SENSITIVITY TO SUPPORT MARKET GROWTH 99
・ TABLE 39 BLOOD SCREENING MARKET FOR TMA, BY REGION, 2021–2028 (USD MILLION) 100
7.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR) 100
7.2.2.1 ELIMINATION OF CONTAMINATION RISKS TO PROPEL MARKET 100
・ TABLE 40 BLOOD SCREENING MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 101
7.3 SEROLOGY/IMMUNOASSAYS 101
・ TABLE 41 KEY PRODUCTS FOR SEROLOGY/IMMUNOASSAYS 101
・ TABLE 42 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 102
・ TABLE 43 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 102
7.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA) 103
7.3.1.1 ULTRA-SENSITIVE AND AUTOMATED FEATURES TO DRIVE MARKET 103
・ TABLE 44 BLOOD SCREENING MARKET FOR CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 103
7.3.2 FLUORESCENT IMMUNOASSAYS (FIA) 103
7.3.2.1 RISING DEMAND FOR SAFE & S・ TABLE REAGENTS TO PROPEL MARKET 103
・ TABLE 45 BLOOD SCREENING MARKET FOR FLUORESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 104
7.3.3 COLORIMETRIC IMMUNOASSAYS/ELISA (CI/ELISA) 104
7.3.3.1 QUALITATIVE AND QUANTITATIVE ANTIGEN MEASUREMENT FOR BLOOD SERUM TO DRIVE MARKET 104
・ TABLE 46 BLOOD SCREENING MARKT FOR COLORIMETRIC IMMUNOASSAYS/ELISA, BY REGION, 2021–2028 (USD MILLION) 105
7.4 RAPID TESTS 105
7.4.1 HIGH EFFICIENCY IN POC DIAGNOSTICS TO PROPEL MARKET 105
・ TABLE 47 KEY PRODUCTS FOR RAPID TESTS 106
・ TABLE 48 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION) 106
7.5 WESTERN BLOT ASSAYS 106
7.5.1 ABILITY TO DETECT RETROVIRUS ANTIBODIES TO DRIVE MARKET 106
・ TABLE 49 KEY PRODUCTS FOR WESTERN BLOT ASSAYS 107
・ TABLE 50 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2021–2028 (USD MILLION) 107
7.6 NEXT-GENERATION SEQUENCING (NGS) 108
7.6.1 EMERGING TECHNOLOGY FOR HIV TESTING TO SUPPORT MARKET GROWTH 108
・ TABLE 51 BLOOD SCREENING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 108
8 BLOOD SCREENING MARKET, BY END USER 109
8.1 INTRODUCTION 110
・ TABLE 52 BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 110
8.2 BLOOD BANKS 110
8.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 110
・ TABLE 53 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION) 111
8.3 HOSPITALS 111
8.3.1 INCREASING SURGICAL PROCEDURES TO PROPEL MARKET 111
・ TABLE 54 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 112
9 BLOOD SCREENING MARKET, BY REGION 113
9.1 INTRODUCTION 114
・ TABLE 55 BLOOD SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION) 114
9.2 NORTH AMERICA 114
・ FIGURE 23 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT 115
・ TABLE 56 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
・ TABLE 57 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
・ TABLE 58 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
・ TABLE 59 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 117
・ TABLE 60 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
・ TABLE 61 NORTH AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 118
・ TABLE 62 NORTH AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 118
・ TABLE 63 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
9.2.1 NORTH AMERICA: RECESSION IMPACT 119
9.2.2 US 119
9.2.2.1 INCREASING PREVALENCE OF HIV AND CHRONIC DISEASES TO DRIVE MARKET 119
・ TABLE 64 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
・ TABLE 65 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
・ TABLE 66 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 121
・ TABLE 67 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
・ TABLE 68 US: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 122
・ TABLE 69 US: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 122
・ TABLE 70 US: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.2.3 CANADA 123
9.2.3.1 RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET 123
・ TABLE 71 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123
・ TABLE 72 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
・ TABLE 73 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 124
・ TABLE 74 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
・ TABLE 75 CANADA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 125
・ TABLE 76 CANADA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 125
・ TABLE 77 CANADA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.3 EUROPE 126
・ TABLE 78 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
・ TABLE 79 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 127
・ TABLE 80 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
・ TABLE 81 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 127
・ TABLE 82 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
・ TABLE 83 EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 128
・ TABLE 84 EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 129
・ TABLE 85 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.3.1 EUROPE: RECESSION IMPACT 129
9.3.2 GERMANY 130
9.3.2.1 HIGH INCIDENCE OF CANCER TO DRIVE MARKET 130
・ TABLE 86 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130
・ TABLE 87 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
・ TABLE 88 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 131
・ TABLE 89 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
・ TABLE 90 GERMANY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 132
・ TABLE 91 GERMANY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 132
・ TABLE 92 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.3.3 FRANCE 133
9.3.3.1 GROWING CASES OF HIV TO PROPEL MARKET 133
・ TABLE 93 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133
・ TABLE 94 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
・ TABLE 95 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 134
・ TABLE 96 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
・ TABLE 97 FRANCE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 134
・ TABLE 98 FRANCE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 135
・ TABLE 99 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
9.3.4 UK 135
9.3.4.1 FAVORABLE GOVERNMENT SUPPORT FOR INFECTIOUS DISEASE SCREENING TO DRIVE MARKET 135
・ TABLE 100 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
・ TABLE 101 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
・ TABLE 102 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 137
・ TABLE 103 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
・ TABLE 104 UK: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 137
・ TABLE 105 UK: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 138
・ TABLE 106 UK: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
9.3.5 ITALY 138
9.3.5.1 GROWING NUMBER OF BLOOD DONORS TO SUPPORT MARKET GROWTH 138
・ TABLE 107 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
・ TABLE 108 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
・ TABLE 109 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 139
・ TABLE 110 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
・ TABLE 111 ITALY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 140
・ TABLE 112 ITALY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 141
・ TABLE 113 ITALY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 141
9.3.6 SPAIN 141
9.3.6.1 RISING ADOPTION OF NAT TECHNOLOGY TO PROPEL MARKET 141
・ TABLE 114 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
・ TABLE 115 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
・ TABLE 116 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 142
・ TABLE 117 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
・ TABLE 118 SPAIN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 143
・ TABLE 119 SPAIN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 144
・ TABLE 120 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 144
9.3.7 REST OF EUROPE 144
・ TABLE 121 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%) 145
・ TABLE 122 REST OF EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
・ TABLE 123 REST OF EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
・ TABLE 124 REST OF EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 146
・ TABLE 125 REST OF EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
・ TABLE 126 REST OF EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 146
・ TABLE 127 REST OF EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 147
・ TABLE 128 REST OF EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 147
9.4 ASIA PACIFIC 147
・ FIGURE 24 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT 148
・ TABLE 129 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
・ TABLE 130 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
・ TABLE 131 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
・ TABLE 132 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 150
・ TABLE 133 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 150
・ TABLE 134 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 150
・ TABLE 135 ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 151
・ TABLE 136 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
9.4.1 ASIA PACIFIC: RECESSION IMPACT 151
9.4.2 CHINA 152
9.4.2.1 HIGH BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET 152
・ TABLE 137 CHINA: KEY MACROINDICATORS 152
・ TABLE 138 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 153
・ TABLE 139 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
・ TABLE 140 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 153
・ TABLE 141 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
・ TABLE 142 CHINA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 154
・ TABLE 143 CHINA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 155
・ TABLE 144 CHINA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 155
9.4.3 JAPAN 155
9.4.3.1 GROWING ADOPTION OF ADVANCED BLOOD SCREENING TECHNOLOGIES TO DRIVE MARKET 155
・ TABLE 145 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156
・ TABLE 146 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
・ TABLE 147 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 157
・ TABLE 148 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
・ TABLE 149 JAPAN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 157
・ TABLE 150 JAPAN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 158
・ TABLE 151 JAPAN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 158
9.4.4 INDIA 158
9.4.4.1 INCREASING ROAD ACCIDENTS TO SUPPORT MARKET GROWTH 158
・ TABLE 152 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159
・ TABLE 153 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
・ TABLE 154 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 160
・ TABLE 155 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
・ TABLE 156 INDIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 161
・ TABLE 157 INDIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 161
・ TABLE 158 INDIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 161
9.4.5 AUSTRALIA 162
9.4.5.1 INCREASING CASES OF LEUKEMIA TO DRIVE MARKET 162
・ TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162
・ TABLE 160 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
・ TABLE 161 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 163
・ TABLE 162 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
・ TABLE 163 AUSTRALIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 163
・ TABLE 164 AUSTRALIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 164
・ TABLE 165 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 164
9.4.6 REST OF ASIA PACIFIC 164
・ TABLE 166 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
・ TABLE 167 REST OF ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
・ TABLE 168 REST OF ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 166
・ TABLE 169 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 166
・ TABLE 170 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 166
・ TABLE 171 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 167
・ TABLE 172 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 167
9.5 LATIN AMERICA 167
・ TABLE 173 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
・ TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168
・ TABLE 175 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
・ TABLE 176 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 169
・ TABLE 177 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
・ TABLE 178 LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 170
・ TABLE 179 LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 170
・ TABLE 180 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 170
9.5.1 LATIN AMERICA: RECESSION IMPACT 171
9.5.2 BRAZIL 171
9.5.2.1 GROWING CANCER BURDEN TO SUPPORT MARKET GROWTH 171
・ TABLE 181 INCIDENCE OF CANCERS IN BRAZIL, 2020 VS. 2025 171
・ TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
・ TABLE 183 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
・ TABLE 184 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 172
・ TABLE 185 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
・ TABLE 186 BRAZIL: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 173
・ TABLE 187 BRAZIL: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 173
・ TABLE 188 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 174
9.5.3 MEXICO 174
9.5.3.1 RISING BLOOD DONATIONS TO SUPPORT MARKET GROWTH 174
・ TABLE 189 MEXICO: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
・ TABLE 190 MEXICO: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
・ TABLE 191 MEXICO: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 175
・ TABLE 192 MEXICO: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
・ TABLE 193 MEXICO: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 176
・ TABLE 194 MEXICO: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 176
・ TABLE 195 MEXICO: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 176
9.5.4 REST OF LATIN AMERICA 177
・ TABLE 196 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
・ TABLE 197 REST OF LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
・ TABLE 198 REST OF LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 178
・ TABLE 199 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
・ TABLE 200 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 178
・ TABLE 201 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 179
・ TABLE 202 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 179
9.6 MIDDLE EAST & AFRICA 179
9.6.1 RISING SURGICAL PROCEDURES DUE TO CHRONIC DISEASES TO FUEL MARKET 179
・ TABLE 203 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
・ TABLE 204 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
・ TABLE 205 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 181
・ TABLE 206 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 181
・ TABLE 207 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 182
・ TABLE 208 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 182
・ TABLE 209 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 183
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 183
10 COMPETITIVE LANDSCAPE 184
10.1 OVERVIEW 184
10.2 STRATEGIES OF KEY PLAYERS 184
10.2.1 BLOOD SCREENING MARKET: OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS 184
・ TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 184
10.3 REVENUE SHARE ANALYSIS 186
・ FIGURE 25 REVENUE SHARE ANALYSIS OF LEADING PLAYERS IN BLOOD SCREENING MARKET 186
10.4 MARKET SHARE ANALYSIS 187
10.4.1 BLOOD SCREENING MARKET 187
・ FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYER (2022) 187
・ TABLE 211 BLOOD SCREENING MARKET: INTENSITY OF COMPETITIVE RIVALRY 187
10.5 COMPANY EVALUATION MATRIX 188
10.5.1 LIST OF EVALUATED VENDORS 188
10.5.2 STARS 189
10.5.3 EMERGING LEADERS 189
10.5.4 PERVASIVE PLAYERS 189
10.5.5 PARTICIPANTS 189
・ FIGURE 27 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 190
10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 191
10.6.1 PROGRESSIVE COMPANIES 191
10.6.2 STARTING BLOCKS 191
10.6.3 RESPONSIVE COMPANIES 191
10.6.4 DYNAMIC COMPANIES 191
・ FIGURE 28 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 192
10.7 COMPETITIVE BENCHMARKING 193
10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193
・ FIGURE 29 BLOOD SCREENING MARKET: PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193
・ TABLE 212 BLOOD SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 193
・ TABLE 213 BLOOD SCREENING MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT ANALYSIS 194
・ TABLE 214 BLOOD SCREENING MARKET: COMPANY REGIONAL FOOTPRINT ANALYSIS 194
・ TABLE 215 BLOOD SCREENING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 194
10.8 COMPETITIVE SCENARIO 195
10.8.1 PRODUCT LAUNCHES 195
・ TABLE 216 BLOOD SCREENING MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−SEPTEMBER 2023) 195
10.8.2 DEALS 196
・ TABLE 217 BLOOD SCREENING MARKET: KEY DEALS (JANUARY 2020−SEPTEMBER 2023) 196
11 COMPANY PROFILES 198
11.1 KEY PLAYERS 198
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
11.1.1 F. HOFFMANN-LA ROCHE LTD. 198
・ TABLE 218 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 198
・ FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 199
11.1.2 GRIFOLS, S.A. 204
・ TABLE 219 GRIFOLS, S.A.: BUSINESS OVERVIEW 204
・ FIGURE 31 GRIFOLS S.A.: COMPANY SNAPSHOT (2022) 205
11.1.3 ABBOTT LABORATORIES 208
・ TABLE 220 ABBOTT LABORATORIES: BUSINESS OVERVIEW 208
・ FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 209
11.1.4 BIO-RAD LABORATORIES, INC. 212
・ TABLE 221 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 212
・ FIGURE 33 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 213
11.1.5 DIASORIN 218
・ TABLE 222 DIASORIN: BUSINESS OVERVIEW 218
・ FIGURE 34 DIASORIN: COMPANY SNAPSHOT (2022) 219
11.1.6 BIOMÉRIEUX 223
・ TABLE 223 BIOMÉRIEUX: BUSINESS OVERVIEW 223
・ FIGURE 35 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 224
11.1.7 BD 226
・ TABLE 224 BD: BUSINESS OVERVIEW 226
・ FIGURE 36 BD: COMPANY SNAPSHOT (2022) 227
11.1.8 DANAHER (BECKMAN COULTER, INC.) 229
・ TABLE 225 DANAHER: BUSINESS OVERVIEW 229
・ FIGURE 37 DANAHER: COMPANY SNAPSHOT (2022) 230
11.1.9 HOLOGIC, INC. 232
・ TABLE 226 HOLOGIC, INC.: BUSINESS OVERVIEW 232
・ FIGURE 38 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 233
11.1.10 SIEMENS HEALTHINEERS AG 236
・ TABLE 227 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 236
・ FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 237
11.1.11 THERMO FISHER SCIENTIFIC, INC. 239
・ TABLE 228 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 239
・ FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 240
11.2 OTHER PLAYERS 243
11.2.1 ORTHO CLINICAL DIAGNOSTICS 243
11.2.2 MERCK KGAA 244
11.2.3 REVVITY (PART OF PERKINELMER INC.) 245
11.2.4 BIO-TECHNE 246
11.2.5 GFE 247
11.2.6 TRINITY BIOTECH 248
11.2.7 J. MITRA & CO. PVT. LTD. 249
11.2.8 MINDRAY 250
11.2.9 MACCURA BIOTECHNOLOGY CO., LTD. 251
11.2.10 IMMUCOR, INC. 252
11.2.11 CELLABS 252
11.2.12 ABNOVA CORPORATION 253
11.2.13 ENZO BIOCHEM, INC. 254
11.2.14 TULIP DIAGNOSTICS PVT. LTD. 254
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.